These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 26377342)

  • 1. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
    [No Abstract]   [Full Text] [Related]  

  • 3. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study.
    Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Ford I;
    Eur J Heart Fail; 2013 Nov; 15(11):1296-303. PubMed ID: 23803951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
    Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
    Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
    Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
    Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
    Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
    Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart rate and its reduction in chronic heart failure and beyond.
    Nikolovska Vukadinović A; Vukadinović D; Borer J; Cowie M; Komajda M; Lainscak M; Swedberg K; Böhm M
    Eur J Heart Fail; 2017 Oct; 19(10):1230-1241. PubMed ID: 28627045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
    Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
    Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
    Komajda M; Böhm M; Borer JS; Ford I; Robertson M; Manolis AJ; Tavazzi L; Swedberg K;
    Eur J Heart Fail; 2014 Jul; 16(7):810-6. PubMed ID: 24961493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.
    Voors AA; van Veldhuisen DJ; Robertson M; Ford I; Borer JS; Böhm M; Komajda M; Swedberg K; Tavazzi L;
    Eur J Heart Fail; 2014 Apr; 16(4):426-34. PubMed ID: 24504937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
    Foster JL; Bobadilla RV
    J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
    Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
    Komajda M; Böhm M; Borer J; Ford I; Krum H; Tase A; Tavazzi L; Swedberg K
    Eur J Heart Fail; 2013 Jan; 15(1):79-84. PubMed ID: 22892123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.